Core Insights - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [2] - The company is advancing its lead candidate, verekitug, which targets the receptor for thymic stromal lymphopoietin (TSLP), into Phase 2 trials for chronic rhinosinusitis with nasal polyps, severe asthma, and chronic obstructive pulmonary disease [2] Upcoming Events - Rand Sutherland, CEO of Upstream Bio, will participate in several investor conferences in November 2025, including the Truist Securities BioPharma Symposium on November 6, Stifel 2025 Healthcare Conference on November 11, and TD Cowen Immunology and Inflammation Summit on November 12 [1][3] - Live webcasts of the presentations will be available on Upstream Bio's website, with replays posted afterward [1]
Upstream Bio to Participate in Upcoming November Investor Conferences